“Optimizing the Treatment Sequence: The Cumulative Clinical Benefit of Treatment Initiation With Deucravacitinib Versus Apremilast over 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis from the POETYK PSO-1 Trial”. 2022. SKIN The Journal of Cutaneous Medicine 6 (6): s62. https://doi.org/10.25251/skin.6.supp.62.